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Abstract: The standardized uptake value (SUV), an indicator of the degree of glucose uptake in
18F-fluorodeoxyglucose positron emission tomography (FDG-PET), has been used for predicting
the clinical behavior of malignant tumors. However, its characteristics have been insufficiently
explored at the genomics level. Here, we aim to identify genomic signatures reflecting prognostic SUV
characteristics in breast cancer (BRC). Through integrative genomic profiling of 3710 BRC patients,
including 254 patients who underwent preoperative FDG-PET, we identified an SUV signature,
which showed independent clinical utility for predicting BRC prognosis (hazard ratio [HR] 1.27, 95%
confidence interval [CI] = 1.12 to 1.45, p = 2.23 × 10−4). The risk subgroups classified by the signature
exhibited mutually exclusive mutation patterns of TP53 and PIK3CA and showed significantly
different responsiveness to immunotherapy. Experimental assays revealed that a signaling axis
defined by TP53–FOXM1 and its downstream effectors in glycolysis–gluconeogenesis, including
LDHA, might be important mediators in the FDG-PET process. Our molecular characterizations
support an understanding of glucose metabolism and poor prognosis in BRC with a high SUV,
utilizable in clinical practice to assist other diagnostic tools.
Keywords: FDG-PET; breast cancer; glucose metabolism; Warburg effect; immune checkpoint inhibitor
1. Introduction
18F-fluorodexoyglucose positron emission tomography (FDG-PET) is utilized for predicting
tumor behavior molecularly and clinically, because this imaging modality accurately reflects tumor
biology [1–4]. In breast cancer (BRC), numerous investigations have shown the contribution of tumor
biology to increased glucose uptake in FDG-PET [5,6] and have demonstrated that the degree of glucose
uptake is associated with aggressive tumor characteristics [7,8]. The standardized uptake value (SUV),
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which represents the degree of glucose uptake in FDG-PET, has been recognized as a prognostic and
predictive factor.
Recent advances in molecular biology support the importance of glucose metabolism in
malignancies [9]. In terms of glucose uptake, FDG-PET is a useful imaging tool for reflecting
glucose metabolism [1]. Therefore, understanding glycolysis associated with FDG-PET in malignancy
may offer novel therapeutic options that target metabolism in BRC. Previous investigations also showed
a significant association between the SUV and prognostic indicators such as estrogen receptor (ER),
progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), or histologic grade in
BRC [1,4,5,10,11], indicating a close relationship between tumor aggressiveness and FDG-PET. Despite
the metabolic or oncogenic significance of FDG-PET imaging, its characteristics have not been fully
explored at the integrative genomics level, which might be because of the complex effects of glucose
metabolism on multiple cancer progression steps. Therefore, there is a crucial need to address this
issue and to identify key biomarkers that can be utilized in clinical practice.
For effective cancer therapy, it is important to classify patients precisely by combining molecular
imaging and genomic techniques. Here, we identified a genomic signature associated with the SUV
derived from FDG-PET in BRC. Using multiple BRC cohorts, we found the prognostic or therapeutic
relevance of the signature. Integrated exploration of SUV, mutational, and gene expression alterations
revealed that patients with a high SUV were responsive to immune checkpoint inhibitor (ICI) treatment,
whose predictive variants were also discovered. Using experimental assays with BRC cell lines
at the transcriptional and protein levels, we also verified a strong interaction between oncogenic
transcription factors and metabolic indicators that were associated with SUV activity.
2. Results
2.1. Transcriptomic Profiling Reflecting SUV Alterations in BRC
Table 1 details the baseline characteristics of the 3710 BRC patients included in this study. Among
the six patient cohorts, we first performed gene expression profiling in the Yonsei University (YSU)
cohort containing 301 BRC patients, including 66 patients with BRC for whom SUV data were available.
To identify a gene expression signature responsible for the SUV, we selected a gene set correlated
with the SUV (Pearson correlation test; p < 0.01; |r| > 0.35). Hierarchical clustering analysis with
1424 genes divided the BRC patients into two subgroups according to the SUV: an SUV-high cluster
(SHC) and an SUV-low cluster (SLC) (Figure S1A). When comparing sample clusters divided by
SUV-correlated genes and subgroups dichotomized by an SUV cut-off (SUV of ≤ 4 or > 4), as used in
our previous studies [1,4], we observed that two criteria demonstrated significantly similar BRC patient
classifications (Fisher’s exact test; p = 1.71 × 10−4; Figure S1A). No difference between recurrences
estimated by these two criteria was observed (Figure S1B), indicating that SUV-correlated genes reflect
the SUV’s prognostic characteristic.
By exploring the expression pattern of 1424 genes, we intuitively found a distinct subset of genes
corresponding to the SUV sample clusters (131 genes surrounding the dashed line in Figure S1A). These
genes were more highly expressed in the SHC than in the SLC. Among them, cell-cycle-, cytokinesis-,
or DNA-repair-associated genes, such as TOP2A, AURKB, FOXM1, and BIRC5, were observed,
implying that SUV-associated subgroups are mediated by these genes. To validate SUV-associated
gene expression patterns, we applied 1424 genes to other independent gene expression data in the YSU
triple-negative breast cancer (TNBC) cohort (n = 84; Table 1), in which SUV data are also available.
A hierarchical cluster analysis revealed significantly similar TNBC patient classifications between SUV
and SUV-correlated genes, in which DNA-repair-associated genes were highly enriched in the SHC
(Figure S1C), consistent with the results in the YSU cohort.
To identify a small gene set that still retains a discriminative power stratifying BRC patients into
the SLC or SHC, we compared two gene sets correlated with the SUV in the YSU and YSU-TNBC
cohorts (Pearson correlation tests; p < 0.01; |r| > 0.35). By intersecting two gene sets, we observed that
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229 genes were common (Figure S2A). Hierarchical clustering analyses with these genes well stratified
BRC patients into SUV-high or SUV-low subgroups in the two cohorts, in which DNA-repair-associated
genes were still highly enriched in the SHC (Figure S2B,C), suggesting a set of the 229 genes that could
be adopted into a diagnostic panel for classifying BRC patients into different risk subgroups (Table S1).












Patients (n) 301 84 104 500 817 1904
Age (years)
Median 47 49 48 55 59 62
Range 22–78 34–77 28–72 24–93 26–90 22–91
Histology (%)
Infiltrating Ductal
Carcinoma 260 (86.38) 74 (88.1) 84 (80.8) 599 (73.3) 1454 (76.37)
Infiltrating Lobular
Carcinoma 7 (2.33) 1 (1.2) 12 (11.5) 143 (17.5) 142 (7.46)
Mucinous Carcinoma 12 (3.99) 1 (1.2) 2 (1.9) 14 (1.7) 22 (1.16)
Medullary Carcinoma 5 (1.66) 2 (2.4) 0 (0) 5 (0.6) 25 (1.31)
Metaplastic Carcinoma 2 (0.66) 1 (1.2) 0 (0) 3 (0.4) 1 (0.05)
Others 15 (4.98) 4 (4.8) 6 (5.8) 54 (6.6) 245 (12.87)
NA 1 (1.2) 500 (100) 15 (0.79)
T classification
T1 108 (35.88) 35 (41.7) 77 (74.0) 219 (26.8) 475 (24.95)
T2 166 (55.15) 46 (54.8) 26 (25.0) 459 (56.2) 800 (42.02)
T3 22 (7.31) 3 (3.6) 1 (1.0) 105 (12.9) 115 (6.04)
T4 0 (0) 0 (0) 0 (0) 34 (4.2) 9 (0.47)
NA 5 (1.66) 500 (100) 505 (26.52)
N classification
N0 161 (53.49) 58 (69.0) 88 (84.6) 182 (36.4) 382 (46.8) 993 (52.15)
N1 83 (27.57) 21 (25.0) 15 (14.4) 189 (37.8) 278 (34) 604 (31.72)
N2 35 (11.63) 4 (4.8) 26 (5.2) 85 (10.4) 204 (10.71)
N3 22 (7.31) 1 (1.2) 0 (0) 58 (7.1) 103 (5.41)
NA 1 (1.0) 103 (20.6) 14 (1.7)
AJCC stage
I 77 (25.58) 29 (34.5) 70 (67.3) 140 (17.1) 470 (24.68)
II 157 (52.16) 50 (59.5) 33 (31.7) 461 (56.4) 681 (35.77)
III 62 (20.6) 5 (6.0) 1 (1.0) 184 (22.5) 280 (14.71)
IV 0 (0) 0 (0) 0 (0) 13 (1.6) 0 (0)
NA 5 (1.66) 500 (100) 19 (2.3) 473 (24.84)
ER
Positive 188 (62.46) 102 (98.0) 243 (48.6) 593 (72.6) 1459 (76.63)
Negative 113 (37.54) 84 (100) 1 (1.0) 243 (48.6) 174 (21.3) 445 (23.37)
NA 1 (1.0) 14 (2.8) 50 (6.1)
PR
Positive 184 (61.13) 85 (81.7) 522 (63.9) 1009 (52.99)
Negative 117 (38.87) 84 (100) 18 (17.3) 251 (30.7) 895 (47.01)
NA 1 (1.0) 500 (100) 44 (5.4)
HER2
Positive 44 (14.62) 1 (1.0) 78 (15.6) 121 (14.8) 236 (12.39)
Negative 216 (71.76) 84 (100) 101 (97.1) 369 (73.8) 417 (51) 1668 (87.61)
NA 41 (13.62) 2 (1.9) 53 (10.6) 279 (34.1)
SUV data availability
Yes 66 (21.9) 84 (100) 104 (100)
No 235 (78.1) 500 (100) 817 (100) 1904 (100)
Adjuvant chemotherapy
Yes 270 (89.7) 83 (98.8) 27 (26.0) 40 (4.9) 396 (20.8)
No 18 (5.98) 1 (1.2) 76 (73.0) 12 (1.5) 1508 (79.2)
NA 13 (4.32) 1 (1.0) 500 (100) 765 (93.6)













Recurrence, n 47 16 1 117 85 623
Death, n 35 5 1 91 120 1103
Median follow-up (month) 93.5 67.5 45.5 30.5 28.9 115.6
Abbreviations: YSU, Yonsei University; TNBC, triple-negative breast cancer; FFPE, formalin-fixed
paraffin-embedded; UNC, University of North Carolina; TCGA, The Cancer Genome Atlas; METABRIC, Molecular
Taxonomy of Breast Cancer International Consortium; NA, not available; ER, estrogen receptor; PR, progesterone
receptor; HER2, human epidermal growth factor receptor-2.
To date, the SUV cut-off for BRC patient classification has not been standardized. Because
the SUV-correlated genes reflected a prognostic characteristic of the SUV, we sought to identify
a threshold of the SUV that corresponded to the gene expression alterations. When BRC patients
were heuristically stratified by expression patterns of 1424 SUV-correlated genes, we observed that
the corresponding SUV cut-off was 4.6 (Figure 1A). When 229 SUV-correlated genes common in both
YSU and YSU-TNBC cohorts were applied, the empirical stratification of patients with BRC still showed
a corresponding SUV cut-off of 4.6 (Figure 1B), which might be a potential criterion of the SUV for
classification of high-risk BRC patients. These results indicate that, although the cut-off was arbitrarily
selected, high-risk BRC patients may be classified by a diagnostic panel consisting of several genes
beyond SUV.
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Figure 1. Comparison of the standard uptake value (SUV) and the expression patterns of SUV-
correlated genes in the multiple breast cancer (BRC) patient cohorts. (A) Comparison of the SUV and 
the gene expression patterns in the YSU cohort. A total of 1424 genes were applied to generate a heat 
map of gene expression from 66 BRC patients whose SUV data were available. Genes were sorted by 
Pearson correlation coefficient between the gene expression level and the SUV. BRC samples were 
also sorted by the SUV. (B) Comparison of the SUV and the expression patterns of 229 genes in the 
YSU cohort. The 229 genes were commonly correlated with the SUV, both in the YSU and YSU-TNBC 
cohorts. (C) Examination of FOXM1 mRNA expression and protein levels using formalin-fixed 
paraffin-embedded (FFPE) tissues in the YSU-FFPE cohort (n = 104). BRC patients were divided into 
two groups by an SUV cut-off of 4.6. The p-value in comparison of mRNA expression was obtained 
by a two-sample t-Test, whereas the p-value in comparison with protein levels was obtained by 
Fisher’s exact test. IHC, immunohistochemistry. 
Among DNA-repair-associated genes, FOXM1 was the top discriminator of the two risk 
subgroups as its mRNA expression levels were strongly correlated with the SUV (Pearson correlation 
test; p = 1.44 × 10−6; r = 0.55). To validate this observation, we also estimated mRNA and protein 
expression levels of FOXM1 in another independent cohort of formalin-fixed paraffin-embedded 
(FFPE) samples (n = 104, the YSU-FFPE cohort; Table 1), whose SUV data were also available. These 
additional assessments confirmed higher expression and nuclear staining patterns of FOXM1 in SUV-
high rather than in SUV-low patients (Figure 1C), suggesting FOXM1 as a key factor to predict SUV 
activity. 
2.2. Biological Insight into the SUV-Associated Genes 
To explore the molecular characteristics compatible with the SUV, functional enrichment 
analysis of 1424 genes reflecting SUV alteration (Figure 1A) was carried out. The analysis results 
revealed that genes involved in cancer, cell cycle, and tissue development were strongly enriched. 
Consistent with the previous result (Figure S1A), a significant number of genes were revealed to be 
involved in DNA replication, recombination, and repair (Figure S3A), indicating that abnormal 
activity of the DNA repair system might markedly induce the poor prognosis of patients with BRC 
in the SHC. 
To identify predominant regulators associated with SUV subgroups, an upstream regulator 
analysis of SUV-associated genes was performed. Examination of the enriched genes displayed 
important activated or inhibited regulators, the strongest overrepresentation of which was the 
predominant activation of FOXM1 (Table S2). Among the significant upstream regulator candidates, 
we sought to identify downstream partners regulated by FOXM1, revealing a FOXM1–AURKB–
CDKN1A signaling axis associated with the SUV subgroups (Figure S3B). FOXM1 formed the 
primary hub of the gene network that was subsequently interconnected with other gene network 
hubs centered on AURKB and CDKN1A. The expression levels of FOXM1 and AURKB were 
Figure 1. Comparison of the standard uptake value (SUV) and the expression patterns of SUV-correlated
genes in the multiple breast cancer (BRC) patient cohorts. (A) Comparison of the SUV and the gene
expression patterns in the YSU cohort. A total of 1424 genes were applied to generate a heat map
of gene expression from 66 BRC patients whose SUV data were available. Genes were sorted by
Pearson correlation coefficient between the gene expression level and the SUV. BRC samples were also
sorted by the SUV. (B) Comparison of the SUV and the expression patterns of 229 genes in the YSU
cohort. The 229 genes were commonly correlated with the SUV, both in the YSU and YSU-TNBC
cohorts. (C) Examination of FOXM1 mRNA expressi n and protein lev ls using formalin-fixed
paraffin-embedded (FFPE) tissues in the YSU-FFPE cohort (n = 104). BRC pati nts were divid into
two groups by an SUV cut-off of 4.6. T e - lue in co parison of mRNA expression was obtained by
a two-sample t-Test, whereas the p-value in comparison with protein levels was obtained by Fisher’s
exact test. IHC, immunohistochemistry.
Among DNA-repair-associated genes, FOXM1 was the top discriminator of the two risk subgroups
as its mRNA expression levels were strongly correlated with the SUV (Pearson correlation test; p = 1.44
× 10−6; r = 0.55). To validate this observation, we also estimated mRNA and protein expression levels of
FOXM1 in another independent cohort of formalin-fixed paraffin-embedded (FFPE) samples (n = 104,
the YSU-FFPE cohort; Table 1), whose SUV data were also available. These additional assessments
confirmed higher expression and nuclear staining patterns of FOXM1 in SUV-high rather than in
SUV-low patients (Figure 1C), suggesting FOXM1 as a key factor to predict SUV activity.
2.2. Biological Insight into the SUV-Associated Genes
To explore the molecular characteristics compatible with the SUV, functional enrichment analysis
of 1424 genes reflecting SUV alteration (Figure 1A) was carried out. The analysis results revealed that
genes involved in cancer, cell cycle, and tissue development were strongly enriched. Consistent with
the previous result (Figure S1A), a significant number of genes were revealed to be involved in DNA
replication, recombination, and repair (Figure S3A), indicating that abnormal activity of the DNA
repair system might markedly induce the poor prognosis of patients with BRC in the SHC.
To identify predominan regulators sociated with SUV subgroups, an upstream r gulator analysis
of SUV-associated genes was performed. Examinatio of he nriched genes displayed important
activated or inhibited regulators, the strongest overrepresentation of which was the pre ominant
activation of FOXM1 (Table S2). Among the significant upstream regulator candidates, we sought to
identify downstream partners regulated by FOXM1, revealing a FOXM1–AURKB–CDKN1A signaling
axis associated with the SUV subgroups (Figure S3B). FOXM1 formed the primary hub of the gene
network that was subsequently interconnected with other gene network hubs centered on AURKB
and CDKN1A. The expression levels of FOXM1 and AURKB were significantly higher in the SHC
than in the SLC in the YSU cohort (two-sample t-test; each p < 0.001; Figure S3C), indicating that
FOXM1–AURKB signaling may be a key genetic determinant associated with poor prognosis of BRC
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in the SHC patients. Although a gene network regulated by CDKN1A was significantly associated
with the SUV subclusters, no significance between CDKN1A expression and the sample clusters was
observed, indicating a contribution of CDKN1A not by gene expression changes, but by other biological
events in the high-risk SHC patients.
We also performed regulator effects analysis via the Ingenuity Pathway Analysis tool (QIAGEN)
to assess which biofunctions were significantly activated by upstream regulators with their effectors.
SUV-associated regulators revealed the top regulator effects, activating cytokinesis and dysregulation of
several cell cycle phases in tumor cells (Figure S3D). In the upper layer of the network, FOXM1, CDKN1A,
and MYC [5], along with other important regulators, regulated many genes in the middle layer, such as
CDC20, AURKB, TOP2A, BIRC5, and CCNE1, which are involved in the cell cycle, cytokinesis, or DNA
repair, consistent with our previous findings (Figure S1A). The expression levels of these genes were
significantly higher in the SHC than in the SLC in the YSU cohort (two-sample t-Test; each p < 0.001;
Figure S3C), indicating a robust property of the SUV compatible with a biological mechanism by which
FOXM1, along with other important regulators, synergistically activates downstream effectors, which
subsequently leads to the dysregulation of cytokinesis or the cell cycle.
2.3. Prognostic Utility of the SUV Signature
The SUV clearly has prognostic significance [1]. We next sought to identify a molecular signature
and to use the signature to verify its prognostic relevance in BRC. Gene expression data from all
301 samples were used to estimate prognosis in the YSU cohort. Hierarchical clustering analysis of
the SUV-associated genes divided BRC patients into SLC and SHC. The disease-free survival (DFS),
cancer-specific survival, and overall survival (OS) rates in the SHC were significantly lower than those
in the SLC (Figure S4A and Figure 2A,B). We also validated the prognostic value of the signature in
the University of North Carolina (UNC) [12], The Cancer Genome Atlas (TCGA) [13], and the Molecular
Taxonomy of Breast Cancer International Consortium (METABRIC) [14] cohorts, in which the SUV
signature was a robust predictor of BRC DFS and OS (Figure S4B–D and Figure 2C,D), consistent with
a previous description of the SUV’s prognostic characteristic [15].
To assess the prognostic independence of the SUV signature, we combined clinical data from
the YSU and UNC cohorts, in which the signature showed significant predictive value for BRC
recurrence, and we applied Cox regression analyses to our signature with known clinicopathological
risk factors. In the univariate and multivariate analyses, the SUV signature showed its statistical
significance for recurrence prediction in BRC (hazard ratio [HR], 1.48; 95% confidence interval [CI],
1.05 to 2.09; p = 0.02; Table 2). Additional analyses in the METABRIC cohort also demonstrated
the signature’s robustness in predicting BRC DFS (HR, 1.27; 95% CI, 1.12 to 1.45; p = 2.23 × 10−4;
Table 2), indicating the independent clinical utility of the SUV signature.
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Table 2. Univariate and multivariate Cox regression analysis of disease-free survival in breast cancer.
Variable
Univariate Multivariate
n HR (95% CI) p-Value n HR (95% CI) p-Value
Combined with YSU and
UNC cohorts
Age (>35 years or not) 681 0.61 (0.38–0.98) 0.04 681 0.74 (0.45–1.25) 0.26
Node status (Positive or
Negative) 681 1.02 (0.65–1.6) 0.93 0.94 (0.58–1.5) 0.79
ER status (Positive or
Negative) 681 0.55 (0.4–0.75) 1.84 × 10−4 0.66 (0.47–0.94) 0.02
HER2 status (Positive or
Negative) 681 1.36 (0.95–1.94) 0.09 1.43 (0.99–2.08) 0.06
SUV-signature (SHC vs.
SLC *) 681 1.78 (1.31–2.42) 2.1 × 10−4 1.48 (1.05–2.09) 0.02
METABRIC cohort
Age (>35 years or not) 1904 0.62 (0.4–0.97) 0.04 1904 1.26 (0.81–1.95) 0.31
Node status (Positive or
Negative) 1904 2.26 (1.92–2.66) 7.07 × 10−23 1.68 (1.46–1.86) 2.88 × 10−16
ER status (Positive or
Negative) 1904 0.58 (0.49–0.69) 7.32 × 10−10 1.04 (0.89–1.21) 0.66
HER2 status (Positive or
Negative) 1904 2.05 (1.67–2.51) 3.57 × 10−12 1.37 (1.14–1.64) 8.27 × 10−4
SUV-signature (SHC vs.
SLC *) 1904 1.74 (1.47–2.05) 1.21 × 10−10 1.27 (1.12–1.45) 2.23 × 10−4
* Predicted outcome in Figure 2 was used for analysis. Abbreviations: HR, hazard ratio; CI, confidence interval; SHC, SUV-high cluster; SLC, SUV-low cluster.
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2.4. Mutational Landscape of SUV Genomic Subtypes in BRC
Based on the transcriptomic and prognostic properties of the SUV signature, we sought to identify
somatic alterations associated with the signature in the TCGA cohort. When the tumor mutation burden
(TMB) was estimated, the TMBs in the SHC were significantly higher than those in the SLC (two-sample
t-Test; p = 0.001; Figure 3A). When the mutation frequencies of the genes in the oncogenic signature
or metabolic pathways were compared between the SLC and SHC, seven genes in the oncogenic
signature and 54 genes in the metabolic pathways showed significantly different mutation frequencies
(Figure S5A). We selected genes with a total mutation frequency of >1% across all BRC patients in
the TCGA cohort and found that four genes in the oncogenic signature and 10 genes in the metabolic
pathways had significantly different mutation rates between the SHC and SLC (Figure 3B). Among
them, TP53 was the top discriminator of the SUV subgroups. The total mutation rate of TP53 was 34.3%,
and the mutation frequency of TP53 in the SHC was significantly higher than that in the SLC (Fisher’s
exact test; p = 8.97 × 10−40). PIK3CA was another significant discriminator of the SUV subgroups.
The total mutation rate of PIK3CA was 34.6%, and the mutation frequency of PIK3CA in the SHC
was significantly lower than that in the SLC (Fisher’s exact test; p = 8.62 × 10−6), demonstrating
a contrasting pattern of mutation frequency to that of TP53 (Figure 3B). When comparing the mutation
patterns between the SLC and the SHC in the METABRIC cohort, we also verified mutually exclusive
mutation patterns of TP53 and PIK3CA between the subtypes (Figure S5B), consistent with the TCGA
cohort results.
We also compared known molecular and histological subtypes with somatic alterations illustrated
by the SUV signature (Figure 3C). Regarding the ER and PR status, we observed significantly higher
frequencies of negative BRC patients in the SHC (Fisher’s exact tests; p = 8.08 × 10−35 and p = 3.03
× 10−28, respectively). The frequencies of ER- or PR-negative status were higher among patients
with mutated TP53 but wild-type PIK3CA than among other patients, regardless of SUV subgroup.
Regarding the HER2 status, moderate statistical significance was found for the difference between SUV
subgroups (Figure 3C), for which we performed a signature-based re-stratification of BRC patients
according to HER2 status. We divided the patients into the subgroups based on the HER2 status (i.e.,
negative, equivocal, or positive) and classified them based on the signature in each HER2 subgroup.
The BRC patients in each HER2 subgroup were clearly classified into the SLC or the SHC, in which
mutually exclusive TP53 and PIK3CA mutation patterns and significant enrichment of ER-negative
status in the SHC were also observed (Figure S6A). These results underscore the independent utility
of the signature, regardless of HER2 status. The frequency of patients with TNBC in the SHC was
profoundly higher than that in the SLC (Fisher’s exact test; p = 2.15 × 10−5), accounting for the poor
prognosis of patients in the SHC. Importantly, the vast majority of TNBC patients were in the subgroup
of patients with mutated TP53 and wild-type PIK3CA (73.2%, 60 of 82 patients with TNBC; Figure 3C).
When a signature-based stratification was applied to only TNBC patients (n = 299) in the METABRIC
cohort, the SUV signature retained the mutually exclusive mutation patterns of TP53 and PIK3CA
between the SHC and the SLC (Figure S6B,C), suggesting the independent utility of the signature in
TNBC. The majority of patients with invasive lobular cancer were in the SLC, while most patients in
the SHC had invasive ductal cancer in the TCGA cohort (Fisher’s exact test; p = 3.65 × 10−19; Figure 3C).
Most BRC patients with LumA were classified into the SLC, whereas many BRC patients with the basal
subtype were classified into the SHC (χ2 test; p = 4.32 × 10−55; Figure 3C).
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Figure 3. Association between standardized uptake value (SUV) subgroups and core molecular features
in breast cancer (BRC). Molecular characteristics of the SUV subgroups were categorized by tumor
mutation burden (TMB) (A), mutations (B), known subtypes (C), and heat maps of gene expression
involved in core pathways (D). BRC samples were ordered by the overall mutation frequency of the genes
involved in the oncogenic signature or metabolic pathways. In the panel of mutations, gene symbols
with a red color indicate involvement in the oncogenic signature, while gene symbols with a green
color indicate involvement in the metabolic pathways. The p-values in the TMB and gene expression
categories were obtained by two-sample t-tests. The p-value in the molecular subtype category was
obtained by the χ2 test, whereas the remaining p-values in the mutation or subtype categories were
obtained by Fisher’s exact tests. DDR, DNA damage response; EMT, epithelial–mesenchymal transition.
Based on the significant relationship between FOXM1 and the SUV activity in the previous results
(Figure 1C and Figure S3), we further sought to identify an association between FOXM1 protein
expression and known important molecular subtypes (LumA, LumB, HER2-negative, and TNBC).
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When estimating FOXM1 protein expression generated by reverse phase protein arrays (RPPA) in
the TCGA cohort, we observed significantly different expression levels of FOXM1 across molecular
subtypes (Figure S6D), indicating that FOXM1 may be a good discriminator well reflecting distinct
molecular characteristics of the known subtypes.
2.5. Association Between the SUV Signature and the Response to Immune Checkpoint Inhibitors (ICIs)
The TMB has been shown to be a useful biomarker for predicting the response to ICIs [16,17].
With a significant difference in the TMB between the SUV subgroups (Figure 3A), we attempted to
identify the predictive value of the SUV signature for ICI treatment response (Figure 3D). When
the expression levels of immune checkpoint genes were investigated, we found significant differences
in the expression between the SUV subgroups, except for PD-L1 (CD274). Since the activation of DNA
damage response and repair (DDR) genes was significantly associated with the ICI response [18],
we also estimated the expression levels of DDR genes, demonstrating that the vast majority of DDR
genes were significantly activated in the SHC. Interestingly, many BRC patients with mutant TP53 and
wild-type PIK3CA showed overall patterns of increased DDR gene expression, implying the predictive
value of mutually exclusive TP53 and PIK3CA mutations for predicting ICI responsiveness. TGFβ
pathway genes were significantly downregulated in the SHC, and epithelial–mesenchymal transition
(EMT) genes were differentially expressed between the SUV subgroups, consistent with the previous
report that TGFβ attenuates the response to ICI [19]. Due to the non-availability of ICI responsiveness
data at the genome level, despite clinical trials for ICI in BRC [20], we alternatively sought to validate
the predictive value of the SUV signature for ICI (atezolizumab, a PD-L1 inhibitor) treatment in
urothelial cancer (UC) [19]. When applying the SUV signature for BRC to the UC cohort, the rate of ICI
responsiveness in the SHC was significantly higher than that in the SLC (Figure S7), indicating that ICI
treatment is a possible option for patients classified into the SHC. Taken together, our findings suggest
that gene expression-based SUV subgroups may reflect ICI responsiveness.
2.6. Experimental Characterization of the SUV Signature Mediated by FOXM1–LDHA Signaling
By observing several genes in the oncogenic or metabolic pathways associated with the SUV
signature (Figure 3), we sought to identify upstream factors regulating FOXM1 and its downstream
effectors (Figure S3B). Re-examination of significantly mutated genes and the SUV signature showed
a strongly overrepresented upstream network of TP53 (Figure S8A). TP53 formed a primary gene
network hub that was subsequently interconnected with another gene network hub centered on
FOXM1. Many genes in the metabolic pathways (i.e., LDHA, PTEN, GART, PDE4B, and POLD1)
were regulated by TP53, among which FOXM1 commonly regulated LDHA, which is involved
in glycolysis–gluconeogenesis. The expression levels of glycolysis–gluconeogenesis genes were
significantly differentiated between the SUV-associated subgroups (two-sample t-tests; each p < 0.05;
Figure S8B–I). In common with the FOXM1 expression (Figure 1C), additional assessments of protein
levels using FFPE tissues in the YSU-FFPE cohort who underwent preoperative FDG-PET confirmed
higher pLDHA cytoplasmic staining in SUV-high than in the SUV-low patients (Figure S8J,K). These
results suggest an additional property of the SUV to reflect glucose metabolism regulated by TP53 and
FOXM1.
In vitro assays using FOXM1 and LDHA were also carried out to verify the SUV characteristics
to support glucose metabolism regulated by FOXM1. By applying the SUV signature into 52 BRC
cell lines, we characterized two BRC cell groups for further studies (Figure S9A). Through further
estimation of the mRNA and protein levels of FOXM1 and LDHA, we selected MDA-MB231 and
BT549 as SHC cell lines and T47D and ZR75-1 as SLC cell lines (Figure 4A, Figure S9B,C, Figure S10,
Figure S11).
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Figure 4. FOXM1 regulates LDHA expression, glucose utilization, and lactate production in breast
cancer (BRC) cells. (A) Comparison between the expression levels of FOXM1 and LDHA in cancer cells
defined as SUV-high cluster (SHC; MDA-MB231 and BT549) and SUV-low cluster (SLC; T47D and
ZR75-1). The left two panels show the mRNA levels of FOXM1 and LDHA as determine by quantitative
polymerase chain reaction (qPCR), and the right two panels show the protein expression l vels of these
two g nes as determin d by Western blotting. (B) I the upper pa els, the SLC cel lines (T47D and
ZR75-1) were transfected ith pcDNA (control) or the FOXM1 ver xpression vector (pFOXM1). In
the bottom panels, the SHC cell lines (MDA-MB231 and BT549) were transfected with scrambled RNA
(scRNA) or siFOXM1. The mRNA levels of FOXM1 and LDHA were measured by quantitative reverse
transcription (qRT)-PCR. (C) The SLC and SHC cells were cultured for 24 h. A lactate assay kit was
used for LDH production analysis, and a colorimetric glucose assay kit was used for glucose utilization
confirmation. The absorbance was measured at 330 mm. Each bar represents the mean ± standard
deviation of three independent experiments; p-values were obtained by two-sample t-tests. * p < 0.05;
** p < 0.01; *** p < 0.001.
When the two SLC cell lines were transfected with pFOXM1, the mRNA and protein levels
of FOXM1, LDHA, and the phosphorylation of LDHA were increased. However, we transfected
the two SHC cell lines with siFOXM1 and confirmed a decrease in the levels of LDHA and pLDHA
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(Figure 4B and Figure S12). We also performed a lactate and glucose uptake assay to investigate whether
FOXM1 expression is associated with lactate production, LDHA activity, and glucose utilization in
BRC cells. From these data, we found that FOXM1 overexpression increased glucose utilization and
lactate production in SLC cells. In contrast, the levels of glucose utilization and lactate production
were decreased in siFOXM1-transfected SHC cells (Figure 4C). These results indicate that FOXM1
transcriptionally regulates the expression of LDHA in BRC, suggesting that the aggressiveness in
the SHC may be modulated by activation of the FOXM1–LDHA signaling pathway.
3. Discussion
The SUV is clinically relevant in BRC prognosis [1]. To uncover the molecular activities in
the FDG-PET process in BRC patients, we analyzed gene expression and mutation data and identified
a signature reflecting the best characteristics of the SUV in multiple BRC cohorts. The prognostic
utility of the SUV signature was robust and validated independently. In terms of mutational patterns,
the signature was significantly associated with mutually exclusive TP53 and PIK3CA mutations. We
also provided clinical evidence that high-risk patients identified by the signature might have a higher
responsiveness to ICI treatment compared to those with low risk. Additionally, a putative signaling
pathway defined by TP53–FOXM1–LDHA might be responsible for the molecular activity determining
the SUV.
On the basis of increased aerobic glycolysis accompanied by glucose uptake in malignant tumors,
FDG-PET is clinically utilized and enables clinicians to measure the degree of glucose uptake by
cancer cells. The SUV, an objective indicator of glucose uptake, is obtained by FDG-PET scanning and
aids the understanding of tumor biology with respect to glucose metabolism. Based on the robust
diagnostic relevance of FDG-PET imaging, the SUV has been applied in various clinical fields, including
molecular PET application such as 89Zr-atezolizumab imaging for predicting the response to ICI-based
immunotherapy [21]. Despite the usefulness of FDG-PET, its characteristics have been poorly surveyed
at the integrative genomics level. Considering that our previous works indicated the clinical value
of the SUV in BRC [1,22], we performed gene expression profiling in BRC patients who underwent
FDG-PET. By multistep investigation, we verified the predictive values of the SUV signature, especially
for ICI treatment response, and the responsible signaling pathway consisting of TP53, FOXM1, and
LDHA. We propose our genomic signature as a basic resource describing the molecular activity
associated with the SUV derived from FDG-PET scanning.
The current study revealed several molecular features and a credible signaling pathway responsible
for SUV-associated activity. Mutation profiling revealed that TP53 and PIK3CA, previously well-known
factors explaining BRC heterogeneity [23–26], were the molecules most significantly distinguished
between the SUV-associated subgroups, suggesting a possible diagnostic method using TP53 and
PIK3CA mutations to support FDG-PET scan performance. The high TMB and distinct activity of
DDR and EMT genes in the SHC subgroup also support the significant value of the SUV signature
as a predictive signature for ICI treatment [16–19]. The signature-based re-stratifications of BRC
patients demonstrated the independent utility of the SUV signature regardless of HER2 or TNBC status,
proposing an aggressive treatment option including ICI-based immunotherapy for the SHC patients
with equivocal molecular status such as HER2-equivocal. Additionally, gene network analysis revealed
that a regulatory relationship between TP53 and FOXM1 was associated with different SUV-associated
activities. Since the oncogenic transcription factor FOXM1 is negatively regulated by the tumor
suppressor TP53 [27], aggressiveness in the SHC may be crucially mediated by TP53. We also observed
that TP53 and FOXM1 regulated LDHA cooperatively. FOXM1 is reported to be associated with tumor
aggressiveness and Warburg effect regulation in several cancers [28–30]. Elevated FOXM1–LDHA
signaling increased cancer cell growth and metastasis [30,31]. In this study, we characterized the roles
of FOXM1 in the Warburg effect in terms of LDH activity, glucose utilization, and lactate production
via the regulation of the expression of LDHA, the key enzyme in aerobic glycolysis. FOXM1 positively
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regulates aerobic glycolysis and aggressiveness in BRC, suggesting that FOXM1–LDHA signaling has
promising new clinical implications for diagnostic and therapeutic strategies.
In conclusion, we identified a genomic signature revealing distinct molecular subtypes of BRC
associated with the SUV obtained from FDG-PET scanning. We also evaluated two clinical aspects
of the signature—prognosis and ICI responsiveness. Our results uncover genomic and metabolomic
characteristics of glucose uptake captured by FDG-PET, supporting an understanding of glucose
metabolism, as well as the poor prognosis of BRC patients with a high SUV. Although our data reveal
a significance of the SUV signature, a further validation study is warranted to identify an easily
assessable biomarker consisting of a small gene set that still robustly retains the SUV activity.
4. Materials and Methods
4.1. Patients and Tissue Samples
We prospectively collected tumor tissues from specimens of surgically resected BRC at
the Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, between July
1997 and December 2007. After applying the exclusion criteria, 301 patients with invasive BRC were
ultimately enrolled for gene expression profiling (n = 301, the YSU cohort). The following patients
were excluded: patients with pure in situ carcinoma of the breast; recurrent or metastatic disease;
bilateral BRC; or BRC of nonepithelial origin, such as phyllodes tumor, sarcoma, or lymphoma; as well
as those receiving neoadjuvant chemotherapy. Among the 301 patients with BRC, the SUV data of
66 patients who underwent preoperative FDG-PET were available. We also collected tumor tissues from
specimens of surgically resected TNBC at the Gangnam Severance Hospital, Yonsei University College
of Medicine, Seoul, Korea (n = 84, the YSU-TNBC cohort). These TNBC samples were independently
collected with the YSU cohort, and their SUV data were also available. For further validation, we also
collected FFPE tissues in other independent BRC patient cohort who underwent preoperative FDG-PET
(n = 104, the YSU-FFPE cohort). Our study was approved by the institutional review board (IRB) of
Gangnam Severance Hospital, Yonsei University, Seoul, Korea (ethic code: 3-2013-0136), in accordance
with the good clinical practice guidelines under the Declaration of Helsinki. The IRB granted a waiver
of written documentation of informed consent from all participants because of the retrospective study
design. Details of the three BRC patient cohorts with SUV data availability are described in Table 1.
4.2. 18F-Fluorodexoyglucose Positron Emission Tomography (FDG-PET)
The procedure for FDG-PET was previously reported [22]. The SUV was calculated by measuring
18F-fluorodexoyglucose uptake by the primary tumor in the region of interest, as follows: SUV =
[maximal radioactivity concentration in the region of interest]/[injected dose/patient weight (kg)].
4.3. RNA Extraction, Microarray Experiments, and Data Processing
Total RNA was isolated by TRIzol reagent (Life Technologies, Carlsbad, CA, USA) according to
the manufacturer’s protocol. For gene expression profiling in the YSU cohort, 500 ng of total RNA
was used for hybridization labeling according to the manufacturer’s protocols (Illumina HumanHT-12
expression BeadChip, version 3.0). Arrays were scanned with an Illumina Bead Array Reader confocal
scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA, USA) according to the manufacturer’s
instructions. For gene expression profiling in the YSU-TNBC cohort, 2 µg of purified total RNA was
used in the One-Cycle Eukaryotic Target Labeling Assay and hybridized to the array for 16 h at 45 ◦C
(Affymetrix Human Genome U133 Plus 2.0 arrays). Arrays were scanned on an Affymetrix GeneChip
3000 7G scanner according to the manufacturer’s instructions.
After scanning, the gene expression data were normalized using quantile normalization in the R
language environment (version 3.5.1). Measured gene expression values were log2 transformed and
median centered across genes and samples.
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4.4. Public Datasets of BRC Patients
Three independent cohorts of patients (n = 3221) with BRC were used for this study. The mRNA
expression (RNA-Seq) data from The Cancer Genome Atlas database was obtained from the cBioPortal
website (http://www.cbioportal.org; n = 817, the TCGA cohort) [13]. We downloaded the mRNA
quantification data (generated by RSEM software), to which log2 transformation and quantile
normalization were applied. To search for mutation profiles of BRC in the TCGA cohort, the variant
data for genes in the oncogenic signature (64 genes) and metabolic pathways (1114 genes) were also
collected from the cBioPortal. We additionally obtained a gene expression dataset of BRC patients
from the University of North Carolina Lineberger Comprehensive Cancer Center (n = 500, the UNC
cohort) [12], which is freely available in the National Center for Biotechnology Information (NCBI)
Gene Expression Omnibus (GEO) database. Gene expression data for the UNC cohort were generated
by combining data from four subpatient cohorts, including GSE18229, GSE20624, GSE2741, and
GSE6128. We also collected mRNA expression data from a study of 1904 BRC patients conducted
by the Molecular Taxonomy of Breast Cancer International Consortium (n = 1904, the METABRIC
cohort) [14]. The variant data of the METABRIC cohort were also obtained from the cBioPortal.
All genomic data used in this study contain patient survival and follow-up time data to estimate
the prognostic relevance of the signatures. The baseline characteristics of the BRC patient cohorts
whose datasets are publicly available are described in Table 1.
4.5. Statistical Analysis
To generate a gene set highly associated with the SUV score, we applied a Pearson correlation test to
the gene expression data from the YSU cohort and selected genes with significant correlation coefficients
with the SUV (|r| > 0.35 and p < 0.01). Using a gene expression data matrix consisting of a gene feature
and its correlated genes, we performed hierarchical clustering analysis with the centered correlation
coefficient as the measure of similarity, and used a complete linkage clustering method. According
to the patient clustering results, the patients were divided into two subgroups. The Kaplan–Meier
method was used to calculate the time to death or recurrence, and differences between the times were
assessed using log-rank statistics. To estimate the independent utility of the signature, we performed
a multivariate Cox regression analysis combined with known clinicopathological risk factors. To
estimate the significance of gene expression differences between the patient subgroups, we performed
a two-sample t-test for each gene.
Gene set enrichment analysis was carried out to identify the most significant gene sets associated
with the disease process, molecular and cellular functions, and physiological and developmental
conditions. The significance of overrepresented gene sets was estimated by Fisher’s exact test. To
explore the relationships among the genes in the signature, we performed an upstream regulator
analysis that searched known targets of each regulator in the dataset and compared their direction of
change to the expected change based on previously published literature. Gene set enrichment and
upstream regulator analyses were performed using Ingenuity Pathway Analysis (QIAGEN, Redwood
City, CA, USA).
To estimate the TMB of each BRC patient in the TCGA cohort, the total number of somatic
mutations was normalized to the exonic coverage of the reference genome (Assembly ID: GRCh38) in
megabases. For mutation profiling of BRC patients, we obtained the oncogenic signature (64 genes)
and metabolic pathway (1114 genes) gene sets from a molecular signature database (MSigDB, version
6.1). To obtain the genes in the oncogenic signature, we downloaded gene sets from the C6 category in
the MSigDB collections. To obtain the genes in the metabolic pathways, we downloaded the Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway gene sets from the C2 category in the MSigDB
and selected the subgene sets associated with metabolism. The full list of metabolic processes with
the included genes in this study is provided in Table S3.
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4.6. Cell Culture
The human BRC cell lines BT549, BT20, T47D, ZR75-1, SKBR3, BT474, and MDA-MB453 were
purchased from the Korean Cell Line Bank. Other cell lines (MDA-MB231 and MCF7) were obtained
from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells from the ATCC
were certified by the results of a short tandem repeat (STR) DNA profiling assay, a cytochrome C
oxidase I assay, and a mycoplasma contamination assay. The nine BRC cell lines were characterized
by the short tandem repeat (STR)-polymerase chain reaction (PCR) method and screened for
mycoplasma contamination.
The BRC cells used in this study were cultured in Roswell Park Memorial Institute (RPMI)-1640
medium (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS, HyClone) and
1% penicillin/streptomycin (HyClone) (hereafter referred to as complete RPMI1640 medium) at 37 ◦C
in 5% CO2.
4.7. Transfection, Plasmids, and Small Interfering RNA (siRNA)
All cells were transfected using jetPRIME reagent (Cat. 114-15, Polyplus Transfection, Inc., NY,
USA) at a ratio of DNA to reagent of 1:3 according to the manufacturer’s protocol. In our previous study,
the pcDNA6-V5-His-tag expression vector was purchased from Invitrogen (Cat. V22020, Carlsbad,
CA) and pFOXM1 was provided by Dr. Ju-Seog Lee (MD Anderson Cancer Centre, TX, USA) [32].
Scrambled RNA (scRNA) was purchased from GenePharma (Shanghai Co., Ltd., China), and siFOXM1
was synthesized at the ST Pharm Oligo center (ST Pharm, Seoul, Korea).
4.8. Quantitative Real-Time (qRT) PCR
The nine BRC cell lines were seeded in a six-well plate at a density of 2 × 105 cells/well in complete
RPMI1640 medium. Cells were transfected for 24 h, and total cellular RNA was isolated using RNAiso
Plus (Cat. 9109, Takara Bio, Inc., Otsu, Japan). Total RNA (500 ng) was isolated, and cDNA was
synthesized as described [32]. qRT-PCR was performed with TB Green Premix Ex Taq (Cat. RR420,
Takara Bio, Inc., Otsu, Japan) on a Bio-Rad CFX96TM Real-time system and a C1000 TouchTM Thermal
Cycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA) under the following thermal cycling conditions:
95 ◦C for 15 s; 30 cycles at 94 ◦C for 30 s, 64 ◦C for 30 s, and 72 ◦C for 15 s; and 72 ◦C for 10 min.
The qRT-PCR primer sequence sets are shown in Table S4.
4.9. Western Blotting and Antibodies
Cells were lysed with radioimmunoprecipitation assay (RIPA) buffer (Cat. IBS-BR002, iNtRON
Biotechnology, Burlington, MA, USA) and the protein concentration was measured by the BSA
method using a PierceTM BCA Protein Assay Kit (Cat. 23227, Thermo Scientific, Rockford, IL, USA).
The antibodies used in immunoblotting were specific for FOXM1 (Cat. A301-532A, Bethyl Laboratories,
Montgomery, TX, USA), LDHA (Cat. sc-137243, Santa Cruz Biotechnology, TX), and β-actin (Cat. 4967,
Cell Signaling Technology, Inc., Danvers, MA, USA).
4.10. Lactate Production and Glucose Utilization Assay
Cells were transfected with plasmids and siRNAs and prepared for glucose utilization and lactate
production assays. The lactate production assay was performed with a Lactate Assay kit according to
the manufacturer’s protocol (Cat. K627-100). For the glucose utilization assay, transfected cells were
incubated for 24 h. Then, the medium was replaced with phenol red-free RPMI supplemented with
1% FBS and 20 mmol/l oxamate sodium, and cells were maintained in continuous culture for 3 days.
The glucose concentration in the medium was measured using a colorimetric glucose assay kit (Cat.
K686-100, BioVision, Inc., Milpitas, CA, USA) and normalized according to cell number [31].
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4.11. Data Availability
The gene expression datasets with SUV data are available in the NCBI GEO public database (https:
//www.ncbi.nlm.nih.gov/geo/) under the data series accession numbers GSE131769 and GSE135565.
5. Conclusions
In this study, a genomic signature exhibiting distinct molecular subtypes of BRC associated
with the SUV obtained from FDG-PET scanning was identified. Two important clinical aspects of
the signature, prognosis and ICI responsiveness, were also evaluated. We also found that a signaling
axis defined by TP53–FOXM1–LDHA might be an important mediator in the FDG-PET process. Our
results uncover genomic and metabolomic characteristics of glucose uptake captured by FDG-PET,
supporting an understanding of glucose metabolism, as well as the poor prognosis of BRC patients
with a high SUV.
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